Marfan is a commonly used drug for the treatment of multiple myeloma and is more effective, but monotherapy is not as effective as combination chemotherapy with other drugs.
Marfan, also known as nitrogen mustard phenylpropionate, Eckland, and melphalan, is the drug of choice for multiple myeloma.
The complete remission rate of single-agent melphalan in the treatment of multiple myeloma is only about 5%, which is significantly higher when combined with prednisone and thalidomide. Marfan is excreted by the kidneys and is less favorable than the VDT regimen (bortezomib, dexamethasone, and thalidomide) in patients with renal impairment.
It should also be noted that Marfan has a myelosuppressive effect, therefore, during the treatment period, frequent monitoring of blood (blood cell count) is necessary, and if necessary, the drug should be suspended or the dose should be adjusted. Marfan is often excreted by the kidneys and is prone to damage hematopoietic stem cells. Therefore, people with renal lesions or those who are preparing for hematopoietic stem cell transplantation should try to avoid the use of this drug in conventional chemotherapy.
It is recommended that a specialist physician choose the appropriate therapeutic drug according to the specific condition.